BioSphere Medical, Inc. Release: Three-Year Data from 1,278 Women Published in Obstetrics & Gynecology Demonstrates Long-Term Efficacy and Durability of Uterine Fibroid Embolization (UFE)

ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere”), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today announced that three-year outcomes data from the FIBROID Registry just published in the January 2008 issue of Obstetrics & Gynecology concluded that over the long term, and in a broad range of practice settings, uterine artery embolization (or “uterine fibroid embolization” or “UFE”) produces a high level of durable symptom control and results in a significant improvement in a woman’s health-related quality of life. Earlier today, the Society of Interventional Radiology (SIR) said, “Three-year data from the largest, multi-center, prospective voluntary registry on any procedure for benign uterine fibroids showed that 90 percent of the women participating avoided a hysterectomy, and of these, 85 percent had a substantial improvement in symptoms and quality of life.” Additional information about UFE, and other links of related interest, can be found on the SIR’s Web site, www.sirweb.org, on BioSphere’s Web site, www.biospheremed.com, and on www.ask4ufe.com.